PVI
TSHA icon

Pura Vida Investments’s Taysha Gene Therapies TSHA Stock Holding History

Pura Vida Investments’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33,822
Closed -$717K – 329
2021
Q2 		$717K Buy
+33,822
New +$780K 0.02% 192
2020
Q4 		– Sell
-10,000
Closed -$224K – 221
2020
Q3 		$224K Buy
+10,000
New +$235K 0.01% 147

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Pura Vida Investments's TSHA Position: Q3 2021 in Review

Pura Vida Investments sold out of Taysha Gene Therapies (TSHA) in Q3 2021, closing a stake of 33,822 shares — an estimated $717K sold.

Pura Vida Investments first reported a position in TSHA in Q3 2020 and held it in 2 quarters. The position peaked at $717K in Q2 2021. 48 funds tracked by Wall St. Rank hold TSHA as of Q3 2021.

  • Pura Vida Investments reported no remaining Taysha Gene Therapies position as of Q3 2021 after selling out during the quarter.
  • Pura Vida Investments sold 33,822 Taysha Gene Therapies shares in Q3 2021, an estimated $717K.
  • Pura Vida Investments first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 2 quarters.
  • Pura Vida Investments's Taysha Gene Therapies position peaked at $717K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2021.

Based on Pura Vida Investments's 13F filing for Q3 2021, filed 15 Nov 2021.